# Unither Pharmaceuticals to acquire Carragelose portfolio from Marinomed Biotech

Marinomed Biotech AG signed an agreement to sell its Carragelose business to Unither Pharmaceuticals for up to EUR 20 million, including upfront and milestone payments, subject to regulatory and shareholder approvals.

- Type: Acquisition
- Announced: 2024-11-19
- Where: France
- Value: $21.0M (20.0M EUR)
- Status: announced
- Products: Carragelose portfolio (medical devices and pharmaceutical products)
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Unither Pharmaceuticals](https://endata.com/companies/81145.md) (acquirer)
- [Marinomed Biotech AG](https://endata.com/companies/81146.md) (target)

## Sources

- [unither-pharma.com](https://www.unither-pharma.com/press-release-acquisition-of-the-carragelose-portfolio-by-unither-pharmaceuticals/), 2024-11-19: "Unither Pharmaceuticals is a leading contract development and manufacturing organization of medical devices and pharmaceutical products with production sites in many parts of the world."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.